Article successfully added.

CyFlow™ CD22 PE-Cy7

CyFlow™ CD22 PE-Cy7
Alternative Name: BL-CAM, SIGLEC-2, SIGLEC2
Antibody: Yes
Antigen: CD22
Application: Flow cytometry
Clonality: monoclonal
Clone: S-HCL-1
Emission Maximum: 785 nm
Excitation Maximum: 496 nm, 565 nm
Field of Interest: Immunophenotyping
Format/Fluorochrome: PE-Cy7
Isotype: IgG2b
Laser: Blue , Green, Yellow
Regulatory Status: RUO
Source Species: Mouse
Target Species: Human
Product number: CN265686

For Research Use Only

Build Your Own Reagent Panel
HLDA Workshop HLDA IV—WS Code B48 Quantity 100 tests Volume 0.4 mL Immunogen... more
CyFlow™ CD22 PE-Cy7
HLDA WorkshopHLDA IV—WS Code B48
Quantity100 tests
Volume0.4 mL
ImmunogenWhole hairy cell leukemia cells and membrane preparation
Background InformationCD22 (Siglec-2; sialic acid-binding immunoglobulin-like lectin-2) is a transmembrane glycoprotein binding α 2,6-linked sialic acid-bearing ligands. Intracellular domain of CD22 recruits protein tyrosine phosphatase SHP-1 through the immunoreceptor tyrosine-based inhibitory motifs (ITIMs), thus setting a treshold for B cell receptor-mediated activation. CD22 also regulates B-cell response by involvement in controlling the CD19/CD21-Src-family protein tyrosine kinase amplification pathway and CD40 signaling. CD22 exhibits hallmarks of clathrin-mediated endocytic pathway.
UsageThe reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4·µl reagent·/ 100·µl of whole blood or 10^6 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Storage BufferThe reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.
Specific References

| Foon KA, Todd RF rd: Immunologic classification of leukemia and lymphoma. Blood. 1986 Jul; 68(1):11324. < PMID: 2809561 > | Huang J, Fan G, Zhong Y, Gatter K, Braziel R, Gross G, Bakke A: Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B‑Cell chronic lymphoproliferative disorders from admixed benign B cells in four‑color multiparameter flow cytometry. Am J Clin Pathol. 2005 Jun; 123(6):826‑32. < PMID: 15899772 > | James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW: Antigen sensitivity of CD22‑specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008 May 15; 180(10):7028‑38. < PMID: 18453625 > | Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ: CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti‑CD22 antibodies to peripheral blood dendritic cells. Cytometry B Clin Cytom. 2009 Jul; 76(4):237‑48. < PMID: 19382197 >